Scarica l'app Stockscreener
0.00
100.00%
-4.97
Dopo l'orario di chiusura:
4.99
4.99
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BLUE Giù?
Forum
Previsione
Precedente Chiudi:
$4.97
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$48.77M
Reddito:
$21.73M
Utile/perdita netta:
$-91.17M
Rapporto P/E:
0.00
EPS:
-0.74
Flusso di cassa netto:
$-286.43M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
Nome
Bluebird Bio Inc
Settore
Industria
Telefono
339-499-9300
Indirizzo
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Confronta BLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
0.00 | 48.77M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Downgrade | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-19 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Iniziato | JP Morgan | Overweight |
| 2023-03-07 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-07 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Reiterato | Barclays | Equal Weight |
| 2021-11-08 | Reiterato | Canaccord Genuity | Hold |
| 2021-11-08 | Downgrade | Goldman | Neutral → Sell |
| 2021-11-08 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Reiterato | Wedbush | Neutral |
| 2021-11-08 | Reiterato | Wells Fargo | Equal Weight |
| 2021-08-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Downgrade | Goldman | Buy → Neutral |
| 2021-08-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Ripresa | William Blair | Mkt Perform |
| 2021-08-09 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Downgrade | Berenberg | Buy → Hold |
| 2021-03-10 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-02-17 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-02-16 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Downgrade | Stifel | Buy → Hold |
| 2020-11-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Iniziato | Mizuho | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-27 | Aggiornamento | Stifel | Hold → Buy |
| 2020-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Ripresa | BofA/Merrill | Buy |
| 2020-02-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-10-01 | Iniziato | Stifel | Hold |
| 2019-08-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Aggiornamento | Maxim Group | Hold → Buy |
Mostra tutto
Bluebird Bio Inc Borsa (BLUE) Ultime notizie
bluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital - MSN
Beta-Thalassemia (B-thal) Market Set to Witness - openPR.com
Sickle Cell Treatment Market 2025 | Advances, Drugs, Therapies & - openPR.com
bluebird bio acquired to scale gene therapy access By Investing.com - Investing.com Canada
Carlyle, SK Capital close deal for bluebird bio, injecting capital for commercial expansion - The Business Journals
Carlyle, SK Capital Partners Close Bluebird Bio Acquisition - marketscreener.com
Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital - marketscreener.com
Bluebird Bio (BLUE) Acquired by Carlyle and SK Capital Partners | BLUE Stock News - GuruFocus
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire
Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal - MSN
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com South Africa
Northern Trust Corp Reduces Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Bluebird Bio (BLUE) Acquisition Nears Completion - GuruFocus
Carlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition - Nasdaq
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - marketscreener.com
Carlyle-Led Group Closes Tender Offer for Bluebird Bio - marketscreener.com
Carlyle and SK Capital to acquire bluebird bio - Investing.com
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer | BLUE Stock News - GuruFocus
Bluebird Bio Beats Investor Suit Over FDA Cancer Warning - Law360
Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads By Investing.com - Investing.com India
Bluebird Bio’s SWOT analysis: biotech firm’s stock faces merger crossroads - Investing.com
Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's
bluebird bio Reminds Stockholders to Act Now to Tender Shares fo - GuruFocus
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital - BioSpace
Bluebird Beats Investor Lawsuit Over FDA Black Box Warning (1) - Bloomberg Law News
High Noon For bluebird (NASDAQ:BLUE) - Seeking Alpha
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
Analysts Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $44.60 - Defense World
Bluebird Beats Patent Case Over Blood Disease Therapies - Law360
Bluebird Wins Patent Fight Over Two High-Priced Gene Therapies - Bloomberg Law News
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Tower Research Capital LLC TRC Reduces Stock Position in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions - BioSpace
Carlyle, SK Capital Partners and bluebird bio Provide Updated Te - GuruFocus
Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions - marketscreener.com
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates - MSN
bluebird bio updates terms of Carlyle, SK Capital buyout By Investing.com - Investing.com Canada
Carlyle and SK Capital boost Bluebird Bio bid, offering flexible payout terms - Private Equity Insights
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - Defense World
Bluebird: Q1 Earnings Snapshot - New Haven Register
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - MSN
Bluebird Bio Inc Azioni (BLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):